Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.

Craig M Kessler Fernando F Corrales-Medina Pier Mannuccio Mannucci Victor Jimenez Yuste Michael D Tarantino

Published in: European journal of haematology (2023)

Indirect comparisons demonstrated that PK-guided, personalized prophylaxis with simoctocog alfa can lead to higher zero bleed rates compared with personalized EHL rFVIII concentrate regimens, albeit with higher weekly doses, and a lower percentage of patients treated twice weekly or less.

Keyphrases

patients undergoing
replacement therapy